Cytokinetics, Incorporated (CYTK) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 South San Francisco, CA, 미국. 현재 CEO는 Robert I. Blum.
CYTK 을(를) 보유 IPO 날짜 2004-04-30, 498 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $8.17B.
Cytokinetics, Incorporated is a late-stage biopharmaceutical company dedicated to discovering, developing, and commercializing small molecule drugs that modulate muscle function and contractility to treat debilitating diseases. The company's pipeline includes omecamtiv mecarbil, a cardiac myosin activator in Phase III trials for heart failure, and reldesemtiv, a skeletal muscle troponin activator in Phase III development for amyotrophic lateral sclerosis and spinal muscular atrophy. Additional candidates in development include aficamten, a cardiac myosin inhibitor in Phase III trials for obstructive hypertrophic cardiomyopathy, alongside earlier-stage programs such as CK-136 and CK-3772271. Founded in 1997 and headquartered in South San Francisco, California, Cytokinetics maintains a strategic alliance with Astellas Pharma Inc. to advance its muscle-focused therapeutic platform.
